Adverum Biotechnologies, Inc. announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company's chief development officer. Dr. Seyedkazemi will serve as a member of Adverum's executive committee and will report to Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. Dr. Seyedkazemi will provide leadership for the company's development programs, including global clinical operations, program strategy and project management.

Dr. Star Seyedkazemi most recently served as vice president, portfolio management for research and development at Pliant Therapeutics. Before joining Pliant, Dr. Seyedkazemi served as associate vice president clinical development at Allergan (acquired by AbbVie in May 2020), where she was responsible for clinical and global program leadership for the development of cenicriviroc for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Dr. Seyedkazemi has more than 16 years of pharmaceutical industry experience in corporate leadership, global drug development program leadership, clinical development and operations, global and U.S. medical affairs, and program management across multiple therapeutics areas, including fibrosis, NASH, hepatitis C and HIV at Allergan, Tobira Therapeutics (acquired by Allergan in November 2016), Gilead Sciences, Johnson & Johnson and Abbott Laboratories, preceded by seven years in HIV clinical care and research.